Neuromodulation of Inflammation and Endothelial Function
NCT05230732
Recruiting
Heart failure with reduced ejection fraction (HFrEF) is a major cause of mortality in United States. Aging is a major risk factor for adverse outcomes associated with HFrEF, with majority of the patient's over the age of 50, continuing to experience symptoms, reduced exercise capacity and poor quality of life. We have previously demonstrated that low level transcutaneous electrical stimulation of the vagus nerve at the tragus (LLTS) suppresses inflammation in patients with atrial fibrillation an... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/10/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Systolic Heart Failure
Register for Updates
Multisite Advancement of Research on Chronic Posttraumatic Headache
NCT05620719
Recruiting
Posttraumatic headache (PTH) is a common and highly disabling consequence of traumatic brain injury (TBI) in U.S. military service members and veterans. Cognitive Behavioral Therapy for PTH has been shown to significantly improve disability outcomes in veterans with persistent PTH when delivered in-person. Telemedicine platforms can dramatically increase access to evidence-based care. However, whether CBT for PTH retains its effectiveness when delivered through a telemedicine platform has yet to... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2025
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California +7 locations
Conditions: Posttraumatic Headache
Register for Updates
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320
Recruiting
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2025
Locations: Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut +53 locations
Conditions: Episodic Migraine
Register for Updates
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
NCT06165341
Recruiting
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease. Fazirsiran is a medicine that reduces the creation of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/10/2025
Locations: St Joseph's Hospital and Medical Center, Phoenix, Arizona +32 locations
Conditions: Alpha1-Antitrypsin Deficiency
Register for Updates
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: NCH Research Institute, Naples, Florida +10 locations
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors
NCT06589596
Recruiting
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 as monotherapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California +36 locations
Conditions: Advanced Solid Tumor
Register for Updates
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017
Recruiting
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +2 locations
Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Register for Updates
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932
Recruiting
The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Hoag Memorial Presbyterian, Newport Beach, California +14 locations
Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants
NCT06877702
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/10/2025
Locations: ICON Lenexa, Lenexa, Kansas +1 locations
Conditions: Healthy Volunteers
Register for Updates
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
NCT06932809
Recruiting
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD),... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
04/10/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Tauopathies
Register for Updates
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055
Recruiting
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Physicians Research Group, LLC, Phoenix, Arizona +111 locations
Conditions: Pain
Register for Updates
Markers of Osteoporosis in Cystic Fibrosis
NCT03921060
Recruiting
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return annually for repeat DEXA scans, micro CT, and blood collection.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/10/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Cystic Fibrosis
Register for Updates